Home | About | Journals | Submit | Contact Us | Français |

**|**Math Med Biol**|**PMC3499073

Formats

Article sections

Authors

Related links

Math Med Biol. 2012 March; 29(1): 95–108.

Published online 2010 December 8. doi: 10.1093/imammb/dqq023

PMCID: PMC3499073

Zhihui Wang

Complex Biosystems Modeling Laboratory, Harvard-MIT (HST) Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital-East, 2301 Building 149,13th Street, Charlestown, MA 02129, USA

Veronika Bordas

Department of Applied Mathematics, Harvard University, Cambridge, MA 02138, USA

Complex Biosystems Modeling Laboratory, Harvard-MIT (HST) Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital-East, 2301 Building 149, 13th Street, Charlestown, MA 02129, USA

Received 2009 October 20; Revised 2010 August 5; Accepted 2010 October 26.

Copyright © The author 2010. Published by Oxford University Press on behalf of the Institute of Mathematics and its Applications. All rights reserved.

This article has been cited by other articles in PMC.

Applying a previously developed non-small cell lung cancer model, we assess ‘cross-scale’ the therapeutic efficacy of targeting a variety of molecular components of the epidermal growth factor receptor (EGFR) signalling pathway. Simulation of therapeutic inhibition and amplification allows for the ranking of the implemented downstream EGFR signalling molecules according to their therapeutic values or indices. Analysis identifies mitogen-activated protein kinase and extracellular signal-regulated kinase as top therapeutic targets for both inhibition and amplification-based treatment regimen but indicates that combined parameter perturbations do not necessarily improve the therapeutic effect of the separate parameter treatments as much as might be expected. Potential future strategies using this *in silico* model to tailor molecular treatment regimen are discussed.

Epidermal growth factor receptor (EGFR) is a transmembrane signalling receptor that is frequently over-expressed in many cancers, including non-small cell lung cancer (NSCLC) (Hirsch *et al.*, 2003). Ligand binding to EGFR leads to receptor tyrosine kinase activation as well as a series of downstream signalling events that stimulate cell proliferation, motility, adhesion and invasion, and the overexpression of EGFR causes cell apoptosis inhibition and resistance to chemotherapy (Mendelsohn & Baselga, 2000). Tyrosine kinase inhibitors (TKIs) of EGFR, such as erlotinib and gefitinib, have thus emerged as therapeutic option for patients with advanced NSCLC (Siegel-Lakhai *et al.*, 2005). Although treatment with these drugs so far has resulted in significant tumour regressions in only 10–20% of NSCLC patients (Janne *et al.*, 2005), the development of novel therapeutic targets continues to be a very active topic in current cancer research.

In recent years, interdisciplinary cancer systems biology has drawn much attention in exploring the quantitative relationship between complicated intra- and intercellular signalling processes and the behaviour they trigger on the microscopic and macroscopic scales (Anderson & Quaranta, 2008; Sanga *et al.*, 2007; Wang & Deisboeck, 2008). Many data-driven mathematical and computational models and analysis methods have been developed, but so far the focus is still mostly on the single-cell level (Aldridge *et al.*, 2006). As demonstrated elsewhere in systems biology (Swameye *et al.*, 2003), sensitivity analysis has been widely accepted as a useful tool for studying pathway parameters and signalling events, which have significant effects on system behaviour. Such *in silico* methods are especially useful when it is not possible or practical to conduct experiments on the living system itself (van Riel, 2006). However, different sensitivity analysis methods may produce different parameter rankings for a specific system outcome (Zhang & Rundell, 2006). Moreover, it is quite common that a parameter that is significant to one specific system outcome may not be significant to others. For example, in a mitogen-activated protein kinase (MAPK) signalling pathway study, MAPK kinase (MEK) dephosphorylation was found to have significant impact on the duration and integrated output, but not the amplitude, of extracellular signal-regulated kinase (ERK) activation (Hornberg *et al.*, 2005). Hence, in some cases, an evaluation function that creates a ‘composite ranking’ indicating the importance of parameters in multiple system outcomes at one time would be more appropriate. In the case of molecular oncology therapy, we believe that the optimal target should lead to tumour control; i.e. it should reduce the ability of cancer cells to grow (and/or cause them to die) as well as diminish cancer cell motility (i.e. reduce invasion and contain metastasis) as much as possible.

We have previously developed a set of multiscale agent-based lung cancer models integrating both molecular and microscopic levels to examine NSCLC growth dynamics in 2D and 3D microenvironments (Wang *et al.*, 2007, 2009). Using the 2D model as the computational platform, we also presented a novel ‘cross-scale’ sensitivity analysis method to identify model parameters that have significant effect on the tumour’s expansion rate (Wang *et al.*, 2008). Here, we introduce a new evaluation measure, termed the ‘therapeutic index (TI)’ function. The main purpose of this formula is to help identify key parameters that are critical in affecting the two main tumour phenotypic traits or ‘outcomes’: on-site tumour growth and spatiotemporal expansion. We employed the 3D model as the simulation platform to evaluate the TI function and then compared current results with those from the previously developed sensitivity analysis. Analysis and comparison results showed that the TI function allows for the ranking of the critical parameters according to their therapeutic values by assessing the influence of changes in parameters on multiple tumour outcomes and thus demonstrate that this function is a more powerful tool for target evaluation.

We briefly reintroduce the main features of the multiscale 3D agent-based NSCLC model (Wang *et al.*, 2009), which encompasses both molecular (signalling pathway) and microscopic (multicellular) scales. At the molecular level, two stimuli, epidermal growth factor (EGF) and transforming growth factor *β* (TGF*β*), trigger downstream signalling through different routes but converge at the activation of the Raf signal. This process then initiates the ERK signalling cascade. Figure 1 shows, in brief, the implemented signalling scheme (see Wang *et al.*, 2009 for detailed pathway kinetics). At the microscopic level, we construct a 3D microenvironment consisting of a discrete cube with 200 × 200 × 200 grid points (Fig. 2); a single distant nutrient source representing a blood vessel is located at grid point (150, 150, 150). A heterogeneous biochemical environment is attained by normally distributing external diffusive chemical cues (EGF, TGF*β*, glucose and oxygen tension) throughout the 3D microenvironment. The assigned initial values of these chemical cues are weighted by the distance of a grid point from the nutrient source. Hence, the nutrient source is the most attractive location for the chemotactically acting tumour cells because it maintains the highest weight for each of the aforementioned four cues. Moreover, throughout the simulation, the concentrations of these four chemical cues are continuously updated at a fixed rate (see Wang *et al.*, 2009 for corresponding equations).

Each cell (agent) carries a self-maintained signalling network, and the computer model records the molecular profile for each cell at every time step. In an earlier work, we proposed an experimentally supported molecularly driven cellular phenotypic decision algorithm (Wang *et al.*, 2007). In brief, phospholipase C*γ* (PLC*γ*) and ERK (two downstream signalling molecules of EGFR) are used to determine the emergence of two important phenotypic traits: migration and proliferation, respectively. Experimental studies have shown that transient acceleration of accumulating PLC*γ* levels leads to cell migration (Dittmar *et al.*, 2002), while that of ERK leads to cell replication (Santos *et al.*, 2007). Therefore, in our model, the rate of change of PLC*γ* determines the cellular migration decision, and the rate of change of ERK dictates a cellular proliferation fate. If a cell decides to migrate or proliferate, it will search for a neighbourhood location to move to or for its offspring to occupy. If there are two or more locations available, the cell will select the one with the highest glucose concentration (this location is referred to as the appropriate location); if there are two or more appropriate locations available, the cell will simply randomly pick one. Generally, tumour cells expand towards the nutrient source since these sites are more permissive with regard to the chemical cues. A simulation run is terminated when the first cell reaches the nutrient source since at this point a tumour is able to metastasize (as the nutrient source represents a blood vessel) and consequently is more difficult to contain and treat. Tumour growth and invasion patterns due to cell proliferation and migration are neither predefined nor intuitive: they emerge as a result of intracellular signalling of individual cells and the dynamic cellular interactions within the framework of the 3D biochemical microenvironment.

In a previous cross-scale sensitivity analysis study (Wang *et al.*, 2008), we used a sensitivity coefficient as an index to evaluate how a change in a single sub-cellular model component affects the overall system response at the microscopic level. This coefficient is calculated by the following equation:

(1)

where *p* represents the parameter that is varied in a simulation and *M* the response of the system; *M*_{0} is obtained by setting all parameters to their reference values, and thus (*M _{i}* –

There are, however, some drawbacks in applying this local sensitivity analysis to target discovery since (1) can show a parameter’s sensitivity to only ‘one’ tumour outcome at a time, i.e. either tumour volume or tumour expansion rate. The equation therefore has to be revised especially with respect to the system output term, *M*, to concurrently evaluate ‘two or more’ tumour outcomes. Moreover, the sensitivity coefficient is a relative value showing the correlative relationship between changes in parameters and tumour outcome, which means that this value cannot be independently used to evaluate tumour outcomes (in our case, to determine the final number of alive cells and simulation steps). We thus seek to solve this problem and present here a TI function that incorporates tumour outcome terms directly:

(2)

where *x* and *y* represent the two tumour outcomes, i.e. simulation steps and the final number of alive cells, respectively; *x _{i}* and

The goal of our simulations, aimed at uncovering high-value therapeutic targets, is clear: by changing parameters separately, we attempt to reduce the cell number (corresponding to tumour growth inhibition) while increasing the number of simulation steps (corresponding to tumour expansion inhibition). Parameters that produce high TIs merit particular attention since, generally, they will produce favourable anti-tumour outcomes and hence will be valuable therapeutic targets. However, when changing a parameter leads to a simulation result with (*x _{i}* >

- Group I: (
*x*,_{i}*y*) {_{i}*x*_{i}*x*_{0},*y*_{i}*y*_{0}, (*x*,_{i}*y*) ≠ (_{i}*x*_{0},*y*_{0})} and - Group II: (
*x*,_{i}*y*) {_{i}*x*_{i}*x*_{0},*y*_{i}*y*_{0}, (*x*,_{i}*y*) ≠ (_{i}*x*_{0},*y*_{0})}.

Figure 3 schematically shows the distribution of the two groups. Tumour outcome values in Group I fulfill the requirements that we set for a therapeutic target. Using these definitions, parameters (along with their variations) will first be classified into these groups before a parameter ranking is produced through (2) for each group. The evaluation process also implies that a parameter that produces an (*x*, *y*) pair in Group II with a large TI value cannot be accepted as a promising therapeutic target because changing the component either decreases simulation steps, increases cell number or both.

The 3D agent-based model was implemented in C/C++. A total of 27 seed cells arranged in a 3 × 3 × 3 cube were initially positioned in the center of the 3D environment. Due to computation intensity, the maximum number of simulation steps for all runs is set to 250, with each time step corresponding to 2.4 h. It takes 10–12 steps for a cell to complete a proliferation process, which is in agreement with experimental data (Hegedus *et al.*, 2000). The diameter of each cell is 10 μm, and in our model, the cell shape has been approximated as a cube so that the volume of each cell is 1000 μm^{3}. For the standard simulation case (the final cell number = 16773; the number of elapsed time steps = 222), the resultant volume (made up of live tumour cells, dead tumour cells and interstitial fractions within the tumour mass) is approximately 3.75 × 10^{−2} mm^{3}. The variation ranges for individual parameters were set to (1) [0.1–0.9]-fold for parameter inhibition and (2) [1.1–2, 3–10]-fold for parameter amplification of their corresponding reference values. Note that we only considered variations of pathway component concentrations in this study. Each of the variations in the parameters was used as the only change of input when running a simulation, and all other parameters were held fixed at their reference values. This process was repeated for all parameter values, and the resulting tumour growth indices (i.e. simulation steps and the final number of live cells) were compiled for further analysis.

Using (1), we calculated sensitivity coefficients for all of the pathway components over the entire predefined variation range for each of the two tumour growth indices. Table 1 shows the parameter sensitivity rankings. As described before, a sensitivity coefficient value only reports how sensitive the system outcome is to a particular parameter and is a relative measure. From Table 1, one cannot determine what variation of which parameter produces a particular tumour outcome because a coefficient value is calculated specific to only one tumour outcome, ignoring others. For example, although EGFR is the most sensitive parameter in both simulation steps and cell number, a 0.9-fold variation in EGFR concentration results in an increase in both tumour outcomes, which does not qualify it to be a therapeutic target. Note that the same 0.9-fold variation in EGFR results in distinct sensitivity coefficient values for different tumour outcomes.

The parameter rankings based on the value of TI for parameter inhibition and amplification are presented in Tables 2 and and3,3, respectively. Under parameter inhibition, MEK with a 0.5-fold variation results in the maximum value in TI, and thus MEK emerges as the number one therapeutic target for this treatment strategy. However, further decreasing the MEK concentration fails to add therapeutic value.

For example, while a variation of 0.4-fold in MEK (Group II section in Table 2) results in an even smaller cell number, it is also accompanied by the ‘adverse effect’ of faster tumour expansion (a smaller number of simulation steps in the standard simulation). Under parameter amplification, ERK with a 1.1-fold variation results in the maximum TI, which implies that increasing the concentration of ERK contributes to an increase in the number of simulation steps and a reduction in the cancer cell number. However, similar to the result for MEK inhibition, further increasing the ERK concentration (e.g. to 1.2-fold) causes faster tumour expansion, thus putting ERK with a 1.2-fold variation into Group II. Figure 4 displays the overall change in TI values for MEK and ERK and depicts a series of selected simulation snapshots for the standard simulation, with MEK set to a variation of 0.4-fold and ERK to a variation of 1.1-fold. As can be seen, the MEK treatment simulation takes longer to finish, and both MEK and ERK treatment cases exhibit a smaller tumour volume than that produced by the standard simulation.

We next sought to gain an understanding of the influence of combined parameter perturbations on tumour outcome, using our cross-scale computer simulation and applying the TI method. The parameters and their variations that we use for this analysis are those in Group I of Tables 2 and and33 for a total of eight parameter variation elements. There are 26 combinations of these elements (note: variation pairs of Ras (0.4-fold) and Ras (4.0-fold), and PKC (0.7-fold) and PKC (2.0-fold) are impossible, and thus are eliminated). Table 4 shows the analysis results. It is somewhat surprising that only 15 out of the 26 variation pairs (about 58%) show a therapeutic gain. Of these 15 pairs, the variation pair of TGFβR (3.0-fold) and PKC (2.0-fold) results in the biggest TI value. More surprisingly, only in two of the variation pairs, PLC*γ* (0.8-fold) and Ras (0.4-fold), and PLC*γ* (0.8-fold) and Ras (4.0-fold), does the simulation obtain a greater TI value than when the parameters of the variation pair were varied individually.

Despite advances in molecular therapies, only modest improvements have been made in the treatment of patients with advanced NSCLC (Horn & Sandler, 2009). We have presented here a new method for evaluating therapeutic NSCLC targets by applying a previously developed multiscale model. Because this computational model links molecular and microscopic scales, we are able to assess the influence of parameters at the molecular level on the tumour’s spatiotemporal behaviour at the microscopic and multicellular level. The most important feature of the method is that it takes both tumour growth measures (simulation steps and cell number) into account, while general local sensitivity analysis only focuses on one system output (Rabitz *et al.*, 1983). Hence, the model presented in this paper is more appropriate for evaluating therapeutic targets when two or more tumour outcomes are involved (as is realistic) than is the general sensitivity analysis method, which only yields the relative information between the system input and output. The comparison results confirm the effectiveness of the new method in yielding parameter rankings based on both main tumour features (growth and motility), which is a significant improvement over local sensitivity analysis.

Since PLC*γ* and ERK have been experimentally proven to play significant roles in cancer cell growth and invasion (Dittmar *et al.*, 2002; Santos *et al.*, 2007), they have been implemented as ‘decision’ molecules in determining a cell’s migration and proliferation fates in this 3D model (Wang *et al.*, 2009). It is thus reasonable to expect them to be more prominent than other parameters in the therapeutic value rankings. Indeed, based on our analysis, PLC*γ* is a therapeutic target under parameter inhibition strategy (Table 2), while ERK qualifies as a valuable target in an amplification regimen (Table 3). What is unexpected, however, is that MEK exceeds PLC*γ* as the most important parameter in the inhibition regimen. We note that it has already been demonstrated experimentally that MEK plays a significant role in the MAPK cascade (Wakeling, 2005). Overall, our result is also in good agreement with another control analysis study on a more complex kinetic model of EGF-induced MAPK signalling where both MEK and ERK have been identified to be critical for cellular signal transduction (Hornberg *et al.*, 2005). It is then straightforward to modify the representation of the signalling pathway (Fig. 1) using parameter rankings provided in Tables 2 and and33 in an effort to graphically represent therapeutic target information. A tentative way to achieve this is shown in Fig. 5 from which one can easily identify which components can serve as therapeutic targets as well as their positions relative to other molecules in the downstream EGFR signalling cascade. For example, it is easy to observe that PKC and Ras can serve as therapeutic targets for both parameter inhibition and amplification treatments.

Signalling pathway with encoded therapeutic value information. Therapeutic targets are presented with a different colour (red for pathway inhibition (a) and blue for parameter amplification (b)) and font size according to their TI rankings; a target with **...**

It can also be deduced from our analysis that targeting a parameter should be conducted in a cautious manner. As shown in Fig. 2a, MEK and ERK can only be considered as therapeutic targets when they are at a variation of 0.5-fold and 1.1-fold, respectively. Other variations in these two parameters do not satisfy the requirements for a therapeutic target; i.e. although some variations result in bigger TIs, the adverse effects preclude them from being effective targets. This finding thus suggests that the amount of molecular-targeted drugs on site represents a significantly important factor where minor fluctuations can quickly change a therapeutic gain into a loss and vice versa.

Because it can track molecular signalling dynamics on a single-cell level, the multiscale computational platform employed in this study can potentially help us understand why MEK with a variation of 0.5-fold and ERK with a variation of 1.1-fold are on the top of the therapeutic target list. We only present some preliminary results here. Figure 6 shows changes in concentration of PLC*γ* over time at both population and single-cell levels for three simulations: the standard simulation, MEK (0.5-fold) and ERK (1.1-fold), respectively. We chose to investigate PLC*γ* because it is the molecular determinant for cell migration in our setup. The cancer cell reaching the nutrient source first is of particular interest because it represents how fast the tumour system expands. From Fig. 6, one sees that this particular cell experiences a greater change in PLC*γ* concentration than does the entire cell population in all three simulations, which may explain why this cell reaches the nutrient source first. Moreover, there is a clear difference between the graphs for MEK (0.5-fold) and the standard simulation, but only a small difference between the graphs for ERK (1.1-fold) and the standard simulation. This result confirms our simulation results on tumour expansion rate (the number of simulation steps): 222 steps for both the standard simulation and ERK (1.1-fold) and 230 steps for MEK (0.5-fold). Furthermore, the emergence of the first new cell in the simulation via proliferation happens later in MEK (0.5-fold) than in the other two simulation cases, which shows the effect MEK inhibition has, at this variation, on suppressing tumour expansion.

Preliminary results of changes in concentration of PLC*γ* over time for three representative simulations: the standard simulation (blue), MEK with a variation of 0.5-fold (green) and ERK with a variation of 1.1-fold (brown). Both the average concentration **...**

The success of molecular-targeted therapeutics is often hindered by the capacity of tumour cells to acquire resistance (Bublil & Yarden, 2007), the onset of which may be delayed by the ‘combination’ of more than one inhibitor. Clinical investigators have begun to evaluate the benefit and efficacy of various drug combinations, e.g. monoclonal antibodies and tyrosine kinase inhibitors (Guarino *et al.*, 2009), anti-receptor therapy with EGFR downstream signalling inhibitors (Milton *et al.*, 2007) and angiogenesis inhibitors (Morabito *et al.*, 2009). Hence, we conducted a set of pilot systemic analyses investigating the effects of combined parameter perturbations on tumour growth and expansion (Table 4). We hypothesized that such a theoretical ‘combination therapy’ would produce a greater decrease in cell number and increase in simulation steps in the tumour system (reflected in a greater TI value) than would individual therapies with the parameters involved in the particular combination therapy. However, only 2 out of 26 variation pairs showed such an improved effect (a 21.6% increase in TI for PLC*γ* [0.8-fold] and Ras [0.4-fold] variation pair and 17.0% increase for PLC*γ* [0.8-fold] and Ras [0.4-fold], compared to the individual parameter perturbation: PLC*γ* [0.8-fold] with TI = 0.1004 [see Table 2]). Hence, in this model, most of the combined parameter perturbations did not show improvement when compared to individual parameter inhibition or amplification treatments. One explanation for this is that the underlying signalling system, represented by a system of differential equations in the model, is a non-linear system, i.e. a change in the cellular responses (output) is not directly proportional to molecular changes (input). Regardless, current clinical trials of multitargeted therapy in NSCLC treatment have indeed only benefited a small percentage of patients who have been treated with chemotherapy and monoclonal antibody therapy (Felip *et al.*, 2007), which, to some degree, confirms our finding where most of the combination therapy examinations failed to show additional therapeutic gain.

In summary, we have presented a new method for evaluating the effect of parameter variations on two or more cancer traits or system outputs at the same time. This TI ranked the pathway components according to their target value in order to achieve tumour control. In the future, other relevant output factors, e.g. cell density and tumour diameter, will be incorporated into the TI equation form as well. We note that TIs can also be used to examine which pathway mutations (to pathway components or their association and dissociation kinetic rates) can be the leading causes of the cancer type implemented *in silico*. Moreover, to facilitate ‘computational target discovery’, we plan to (1) integrate more interconnected signalling pathways that play key roles in cancer initiation and progression and (2) revise the current model to understand tumour responses to different drug dosing regimen, e.g. continuous and periodic drug infusion. We argue that the TI method paired with the cross-scale capacities of such advanced agent-based modelling lend themselves to a more integrated approach of studying the therapeutic susceptibility of signalling pathways in cancer.

**Funding**

This work has been supported in part by the National Institutes of Health (grant CA 113004) and by the Harvard-MIT (HST) Athinoula A. Martinos Center for Biomedical Imaging and the Department of Radiology at Massachusetts General Hospital.

- Aldridge BB, Burke JM, Lauffenburger DA, Sorger PK. Physicochemical modelling of cell signalling pathways. Nat Cell Biol. 2006;8:1195–203. [PubMed]
- Anderson AR, Quaranta V. Integrative mathematical oncology. Nat Rev Cancer. 2008;8:227–234. [PubMed]
- Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol. 2007;19:124–134. [PubMed]
- Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zanker KS, Brandt BH. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. Faseb J. 2002;16:1823–1825. [PubMed]
- Felip E, Santarpia M, Rosell R. Emerging drugs for non-small-cell lung cancer. Expert Opin Emerg Drugs. 2007;12:449–460. [PubMed]
- Guarino MJ, Schneider CJ, Hosford MA, Brahmer JR, Rudin CM, Finckenstein FG, Philip-Norton RE, Lu H, Weber MR, Ettinger DS. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist. 2009;14:119–124. [PubMed]
- Hegedus B, Czirok A, Fazekas I, B’Abel T, Madar’asz E, Vicsek T. Locomotion and proliferation of glioblastoma cells in vitro: statistical evaluation of videomicroscopic observations. J Neurosurg. 2000;92:428–434. [PubMed]
- Hirsch FR, Varella-Garcia M, Bunn PA, Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798–3807. [PubMed]
- Horn L, Sandler A. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res. 2009;15:5040–5048. [PMC free article] [PubMed]
- Hornberg JJ, Binder B, Bruggeman FJ, Schoeberl B, Heinrich R, Westerhoff HV. Control of MAPK signalling: from complexity to what really matters. Oncogene. 2005;24:5533–5542. [PubMed]
- Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005;23:3227–3234. [PubMed]
- Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550–6565. [PubMed]
- Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer. 2007;110:599–605. [PubMed]
- Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist. 2009;14:378–390. [PubMed]
- Rabitz H, Kramer M, Dacol D. Sensitivity analysis in chemical kinetics. Ann Rev Phys Chem. 1983;34:419–461.
- Sanga S, Frieboes HB, Zheng X, Gatenby R, Bearer EL, Cristini V. Predictive oncology: a review of multidisciplinary, multiscale in silico modeling linking phenotype, morphology and growth. Neuroimage. 2007;37:S120–S134. [PMC free article] [PubMed]
- Santos SD, Verveer PJ, Bastiaens PI. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat Cell Biol. 2007;9:324–330. [PubMed]
- Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa) Oncologist. 2005;10:579–589. [PubMed]
- Swameye I, Muller TG, Timmer J, Sandra O, Klingmuller U. Identification of nucle-ocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling. Proc Natl Acad Sci USA. 2003;100:1028–1033. [PubMed]
- van Riel NA. Dynamic modelling and analysis of biochemical networks: mechanism-based models and model-based experiments. Brief Bioinform. 2006;7:364–374. [PubMed]
- Wakeling AE. Inhibitors of growth factor signalling. Endocr Relat Cancer. 2005;12:S183–S187. [PubMed]
- Wang ZH, Birch CM, Deisboeck TS. Cross-scale sensitivity analysis of a non-small cell lung cancer model: linking molecular signaling properties to cellular behavior. Biosystems. 2008;92:249–258. [PMC free article] [PubMed]
- Wang Z, Birch CM, Sagotsky J, Deisboeck TS. Cross-scale, cross-pathway evaluation using an agent-based non-small cell lung cancer model. Bioinformatics. 2009;25:2389–2396. [PMC free article] [PubMed]
- Wang ZH, Deisboeck TS. Computational modeling of brain tumors: discrete, continuum or hybrid? Sci Model Simul. 2008;15:381–393.
- Wang Z, Zhang L, Sagotsky J, Deisboeck TS. Simulating non-small cell lung cancer with a multiscale agent-based model. Theor Biol Med Model. 2007;4:50. [PMC free article] [PubMed]
- Zhang Y, Rundell A. Comparative study of parameter sensitivity analyses of the TCR-activated Erk-MAPK signalling pathway. Syst Biol (Stevenage) 2006;153:201–211. [PubMed]

Articles from Mathematical Medicine and Biology are provided here courtesy of **Oxford University Press**

PubMed Central Canada is a service of the Canadian Institutes of Health Research (CIHR) working in partnership with the National Research Council's Canada Institute for Scientific and Technical Information in cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine(NCBI/NLM). It includes content provided to the PubMed Central International archive by participating publishers. |